Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Greenwich LifeSciences reports progress in FLAMINGO-01 trial
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...
Greenwich LifeSciences provides update on FLAMINGO-01 open label HLA data
Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...
Yahoo Finance14d
Greenwich LifeSciences, Inc. (GLSI)
Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.
Seeking Alpha15d
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend
Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...
Investing18d
Greenwich Lifesciences Inc (GLSI)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) today announced the initiation of clinical sites in Germany.The Company has partnered with GBG (German Breast Group), the largest... Snehal Patel ...